Showing 1 - 10 of 17
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by …
Persistent link: https://www.econbiz.de/10010223101
This paper studies interaction of pharmaceutical regulation and parallel trade in a North-South framework. An … South being larger if both countries regulate as compared to only the South limiting reimbursement. Stricter regulation, i …
Persistent link: https://www.econbiz.de/10011290061
This paper analyzes a maximum price system and a reference price system in a vertical differentiation model with a brand-name drug and a generic. In particular, both instruments are compared with respect to their performance in reducing public expenditure, limiting financial exposure of...
Persistent link: https://www.econbiz.de/10010224844
Persistent link: https://www.econbiz.de/10011527587
manufacturer) on pharmaceutical regulation in a North-South framework with a firms endogenous decision to export to the South … via reimbursement limits.Parallel trade may relax regulation in the source country of parallel imports (South) and … intensify regulation in the destination country (North): In the source country, parallel trade may relax regulation both under a …
Persistent link: https://www.econbiz.de/10012889817
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by …
Persistent link: https://www.econbiz.de/10013061754
Persistent link: https://www.econbiz.de/10013263153
manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South … via reimbursement limits. Parallel trade may relax regulation in the source country of parallel imports (South) and … intensify regulation in the destination country (North): In the source country, parallel trade may relax regulation both under a …
Persistent link: https://www.econbiz.de/10011986314
This paper analyzes a maximum price system and a reference price system in a vertical differentiation model with a brand-name drug and a generic. In particular, both instruments are compared with respect to their performance in reducing public expenditure, limiting financial exposure of...
Persistent link: https://www.econbiz.de/10014150467